


Thyroid Eye Disease Treatment Market to Reach \$4.23B by 2032 | Biologics & New Therapies Drive 5.92% CAGR

Thyroid Eye Disease Treatment (TED) Treatment is not exclusive to adults. Children with graves' disease are also susceptible, which create a possible market

WILMINGTON, DE, UNITED STATES, October 9, 2025 /EINPresswire.com/ -- Explore the [Thyroid Eye Disease Treatment Market](#), valued at USD 2.67B in 2024, projected to reach USD 4.23B by 2032 at a CAGR of 5.92%. Key drivers include Teprotumumab, biologics, pediatric therapies, and global market growth.



Thyroid Eye Disease Treatment Market Overview:

“

“Thyroid Eye Disease Treatment Market is set to soar from USD 2.67B in 2024 to USD 4.23B by 2032 at 5.92% CAGR, driven by Teprotumumab, biologics, pediatric therapies, and innovative treatments.”

”

Dharti Raut

Thyroid Eye Disease (TED) Treatment Market is poised for explosive global growth, projected to surge from USD 2.67B in 2024 to USD 4.23B by 2032 at a 5.92% CAGR, driven by rising thyroid disorders, including Graves' disease affecting over 750 million people worldwide. Innovative biologics, Teprotumumab, pediatric therapies, and personalized treatment options are accelerating market adoption, while early diagnosis and advanced imaging expand patient access. North America leads with FDA-approved therapies, Europe thrives on strong R&D and regulatory support, and Asia-Pacific emerges as a high-growth hub with cost-effective treatments. Key players like Amgen, Pfizer, Roche, Novartis, and Sanofi intensify competition, with strategic investments offering high ROI

and unlocking untapped opportunities in ocular care, targeted biologics, and advanced TED management.

Report Title: Global Thyroid Eye Disease Treatment Market
Report ID: 2767
<https://www.stellarmr.com/report/request-sample/thyroid-eye-disease-treatment-market/2767>

Global Thyroid Eye Disease Treatment Market Segments Covered	
By Route of Administration	Parental Administration
	Topical Administration
By Distribution	Hospital Pharmacy
	Online Pharmacy
	Retail Pharmacy
By End User	Hospital
	Clinics
	Other
By Region	North America- United States, Canada, and Mexico
	Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe
	Asia Pacific – China, South Korea, Japan, India, Australia, Indonesia, Philippines, Malaysia, Vietnam, Thailand, Rest of APAC
	Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa
	South America – Brazil, Argentina, Rest of South America

Thyroid Eye Disease Treatment Market Poised for Explosive Growth as Graves’ Disease Cases Skyrocket Globally

Thyroid Eye Disease Treatment Market is set to surge as the global prevalence of thyroid disorders, particularly Graves’ disease, rises dramatically. With over 750 million people affected worldwide and 1% of the U.S. population living with hyperthyroidism, demand for cutting-edge TED therapies, including Teprotumumab, biologics, and personalized treatments, is accelerating. Growing awareness and innovative treatment options are driving the market toward unprecedented growth, unlocking exciting opportunities in ocular care and advanced thyroid eye disease management.

Pediatric Thyroid Eye Disease Treatment Market Set to Soar as Childhood Graves’ Cases Reveal Untapped Opportunities

Thyroid Eye Disease (TED) treatments have traditionally focused on adults, emerging data reveal a growing need for pediatric-specific therapies. With 0.02% of U.S. children diagnosed with hyperthyroidism annually and increasing awareness of TED in adolescents, demand for child-friendly biologics, Teprotumumab, and personalized therapies is set to soar. This untapped segment presents an exciting opportunity for pharmaceutical companies to innovate, develop age-appropriate treatments, and shape the future of pediatric thyroid eye disease care.

Regulatory Hurdles Threaten Thyroid Eye Disease Treatment Market, but Innovative TED Therapies Could Turn Risks into Opportunities

Thyroid Eye Disease (TED) Treatment Market faces significant headwinds as FDA drug approvals remain a lengthy and costly process. On average, new TED therapies take 8–12 years for approval, with only 10% of investigational drugs successfully reaching the market. Regulatory hurdles, including strict Phase III trials and rigorous safety assessments, can stall the introduction of innovative TED therapies, biologics, and Teprotumumab treatments, sometimes costing over USD 2.6 billion per drug. To navigate these challenges, pharmaceutical companies should prioritize early regulatory engagement and adaptive clinical strategies, turning potential risks into opportunities for pioneering therapies in thyroid eye disease care.

Thyroid Eye Disease Treatment Market Soars as Parental Biologics and Hospital-Led Care Drive Unprecedented Growth

Thyroid Eye Disease Treatment Market is driven by both route of administration and end-use industry, with parental administration, including intravenous biologics like Teprotumumab, leading due to rapid symptom relief and targeted action for severe TED cases, while topical treatments support milder symptoms. Hospitals dominate as end users, providing advanced therapies and surgical care, supported by clinics and other providers, with distribution via hospital, online, and retail pharmacies expanding patient access. These segments collectively highlight the growing demand for innovative TED therapies, biologics, and personalized treatment options, making the market dynamic and full of opportunities.

Key Trends Driving Innovation in the Thyroid Eye Disease Treatment Market

Development of Biologics: Monoclonal antibodies like Teprotumumab are transforming the Thyroid Eye Disease Treatment Market by targeting the IGF-1 receptor to modulate immunity and reduce inflammation.

Increased Awareness and Early Diagnosis: Growing awareness and advanced imaging tools enable earlier Thyroid Eye Disease (TED) detection and faster treatment initiation.

Key Development: Amgen Secures TEPEZZA® Approval in Japan, Expanding Global Thyroid Eye Disease Treatment Market Leadership

September 24, 2024 – Amgen (NASDAQ: AMGN) gains Japan MHLW approval for TEPEZZA® to treat active Thyroid Eye Disease (TED), boosting its leadership in the TED Treatment Market.

Innovative Biologics and FDA Approvals Drive North America's Leadership in Thyroid Eye Disease Treatment Market

North America dominates the Thyroid Eye Disease Treatment Market, driven by advanced healthcare infrastructure, high prevalence of thyroid disorders, and rapid adoption of innovative biologics like Teprotumumab. With 1 in 8 U.S. women at risk of thyroid issues and strong R&D investment, major pharmaceutical players are fuelling market expansion. Ongoing awareness campaigns and FDA-approved targeted therapies position the region for sustained growth and leadership in the global TED treatment landscape.

StellarMR is a leading provider of market research reports. For more information, visit our website:

https://www.stellarmr.com/report/req_sample/thyroid-eye-disease-treatment-market/2767

Global Thyroid Eye Disease Treatment Market Heats Up: Biologics, Teprotumumab, and Biosimilars Fuel Fierce Competition

Thyroid Eye Disease Treatment Market is dominated by leading drug and biotech companies focusing on biologics and monoclonal antibody therapies. In North America, major players like Magen, Viridian Therapeutics, and Physics leverage FDA-approved drugs such as Teprotumumab. Europe thrives on strong R&D investment and regulatory support, with Novartis, Sanofi, and GlaxoSmithKline driving innovation. Meanwhile, Asia-Pacific emerges as a high-growth hub, led by HanAll Biopharma and Dr. Reddy's Laboratories, offering cost-effective treatments and expanding patient awareness. Rising competition from targeted biologics, biosimilars, and personalized medicine is reshaping the market, though regulatory hurdles and high development costs remain key challenges, creating opportunities for strategic innovation.

Thyroid Eye Disease Treatment Market Key Players:

North America

Horizon Therapeutics (United States)
Amgen (United States)
Pfizer (United States)
Regeneron Pharmaceuticals (United States)
Bristol-Myers Squibb (United States)
Novartis (United States)
Bausch Health (Canada)

Europe

Roche (Switzerland)
Novartis International (Switzerland)
Merck KGaA (Germany)
Sanofi (France)
AstraZeneca (United Kingdom)
GlaxoSmithKline (United Kingdom)
Swedish Orphan Biovitrum - Sobi (Sweden)
LEO Pharma (Denmark)

Asia Pacific

Takeda Pharmaceutical (Japan)
Daiichi Sankyo (Japan)
Fosun Pharma (China)
Sun Pharma (India)
Dr. Reddy's Laboratories (India)
Samsung Bioepis (South Korea)
CSL Limited (Australia)

Middle East & Africa

Teva Pharmaceutical (Israel)

Aspen Pharmacare (South Africa)

South America

Eurofarma (Brazil)

Aché Laboratórios (Brazil)

Elea Phoenix (Argentina)

Analyst Perspective:

Thyroid Eye Disease (TED) Treatment Market is set for rapid global growth, fueled by rising thyroid disorders and Graves' disease affecting 750M+ people. Biologics, Teprotumumab, and personalized therapies are driving adoption and revenue potential. North America leads with FDA-approved biologics, Europe excels via R&D and regulatory support, and Asia-Pacific grows through cost-effective treatments. Key players like Amgen, Pfizer, and Roche intensify competition, while pediatric treatments and early diagnosis offer untapped opportunities. Strategic investments promise strong ROI, making TED a high-potential, innovation-driven sector.

StellarMR provides a comprehensive report on the Thyroid Eye Disease Treatment Market, covering market size, growth, key players, and future trends. The report is available for purchase on the StellarMR website.

https://www.stellarmr.com/report/req_sample/thyroid-eye-disease-treatment-market/2767

FAQ

Q1: What is the expected growth of the Thyroid Eye Disease Treatment Market?

A1: The market is projected to grow from USD 2.67B in 2024 to USD 4.23B by 2032 at a 5.92% CAGR.

Q2: Which therapies are driving the Thyroid Eye Disease Treatment Market?

A2: Teprotumumab, biologics, pediatric therapies, and personalized treatments are key growth drivers.

Q3: Who are the major players in the global Thyroid Eye Disease Treatment Market?

A3: Leading companies include Amgen, Pfizer, Roche, Novartis, Sanofi, Horizon Therapeutics, and Dr. Reddy's Laboratories.

Maximize Market Research is launching a subscription model for data and analysis in the

Dental Materials market <https://www.mmrstatistics.com/markets/461/healthcare>

About Stellar Market Research

Established in 2018, Stellar Market Research is India Based consulting and advisory firm focused on helping clients to reach their business transformation objectives with advisory services and strategic business. The company's vision is to be an integral part of the client's business as a strategic knowledge partner. Stellar Market Research provides end-to-end solutions that go beyond key research technologies to help executives in any organization achieve their mission-critical goals.

Contact Us :

Address

Phase 3, Navale IT Zone, S.No. 51/2A/2, Office No. 202, 2nd floor, Near, Navale Brg, Narhe, Pune, Maharashtra 411041

Email

sales@stellarmr.com

Mobile

+91 9607365656

Lumawant Godage

Stellar Market Research

+ +91 98606 63688

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/856726682>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.